Microbot Medical Expands US Clinical Infrastructure in Support of the Upcoming IDE Submission to Commence its First in Human Clinical Study
18 1월 2024 - 9:20PM
Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative
LIBERTY® Endovascular Robotic Surgical System, today announced that
following the recent positive results of its pivotal GLP
Pre-Clinical Study, and to support its anticipated IDE submission
to commence its first in human clinical trial, the Company added a
US- based Clinical Research Associate (CRA). The CRA will join the
already established clinical team in the USA, led by Dr. Juan
Diaz-Cartelle, the Company’s Chief Medical Officer.
"Following the successful completion of our
pivotal GLP pre-clinical trial, and as we are in the final stage of
submitting our IDE, having an in house CRA is a key piece for
establishing the right infrastructure for clinical trial execution"
said Dr. Diaz-Cartelle, Chief Medical Officer.
About Microbot MedicalMicrobot
Medical Inc. (NASDAQ: MBOT) is a pre-clinical medical device
company that specializes in transformational micro-robotic
technologies, with the goals of improving clinical outcomes for
patients and increasing accessibility through the natural and
artificial lumens within the human body.
The LIBERTY Endovascular Robotic Surgical System
aims to improve the way surgical robotics are being used in
endovascular procedures today, by eliminating the need for large,
cumbersome, and expensive capital equipment, while reducing
radiation exposure and physician strain. The Company believes the
LIBERTY Endovascular Robotic Surgical System’s remote operation has
the potential to be the first system to democratize endovascular
interventional procedures.Further information about Microbot
Medical is available at http://www.microbotmedical.com.
Safe Harbor
Statements to future financial and/or operating
results, future growth in research, technology, clinical
development, and potential opportunities for Microbot Medical Inc.
and its subsidiaries, along with other statements about the future
expectations, beliefs, goals, plans, or prospects expressed by
management, constitute forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 and
the Federal securities laws. Any statements that are not historical
fact (including, but not limited to statements that contain words
such as “will,” “believes,” “plans,” “anticipates,” “expects” and
“estimates”) should also be considered to be forward-looking
statements. Forward-looking statements involve risks and
uncertainties, including, without limitation, market conditions,
risks inherent in the development and/or commercialization of
potential products, including LIBERTY, the outcome of its studies
to evaluate LIBERTY, whether the Company’s core business focus
program and cost reduction plan are sufficient to enable the
Company to continue to focus on its LIBERTY technology while it
stabilizes its financial condition and seeks additional working
capital, any failure or inability to recruit physicians and
clinicians to serve as primary investigators to conduct regulatory
studies which could adversely affect or delay such studies,
uncertainty in the results of pre-clinical and clinical trials or
regulatory pathways and regulatory approvals, disruptions resulting
from new and ongoing hostilities between Israel and the
Palestinians, such as employees of Microbot and its vendors and
business partners being called to active military duty, any
lingering uncertainty resulting from the COVID-19 pandemic, need
and ability to obtain future capital, and maintenance of
intellectual property rights. Additional information on risks
facing Microbot Medical can be found under the heading “Risk
Factors” in Microbot Medical’s periodic reports filed with the
Securities and Exchange Commission (SEC), which are available on
the SEC’s web site at www.sec.gov. Microbot Medical disclaims any
intent or obligation to update these forward-looking statements,
except as required by law.
Investor Contact:
Michal Efraty+972-(0)52-3044404IR@microbotmedical.com
Microbot Medical (NASDAQ:MBOT)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Microbot Medical (NASDAQ:MBOT)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024